The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.
The conversation is about a user running out of finasteride and seeking advice on alternatives or temporary solutions. Suggestions include trying different brands, using online prescribers, adjusting dosage, or considering a break from the medication.
OP is considering adding topical bimatoprost or latanoprost to their hair loss treatment, which already includes oral minoxidil, and is seeking reliable sources for these products. Users discuss the effectiveness and sourcing of these treatments, with some using bimatoprost for both hairline and eyelashes, and others planning to use latanoprost mixed with finasteride.
Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.
The user has been using 0.25% topical finasteride for eight months with slight improvement and is considering switching to oral finasteride for convenience and potentially better results. Increasing the topical concentration to 0.33% or 0.5% is also an option, but oral finasteride may have more systemic side effects.
PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.
The conversation is about making topical finasteride using ethanol. The user is advised to use non-denatured or food-grade ethanol, as denatured ethanol may be harmful with prolonged skin exposure.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
Dutasteride and finasteride can cause watery ejaculate, which may persist for some users. Zinc supplements or switching to topical treatments are suggested to alleviate this side effect.
Crushing finasteride pills into stemoxydine may not be effective without removing the coating first. It's unclear if the pills dissolve completely or settle as sediment.
The conversation is about analyzing receded temple closeups for signs of fibrosis, scarring, or androgenetic alopecia (AGA). Specific treatments like Minoxidil, finasteride, or RU58841 are not mentioned in the conversation.
The conversation discusses using supplements like zinc, L-Arginine, and ginseng to counteract finasteride side effects like lower libido and lack of morning erections. Users share their experiences with finasteride, noting varied side effects and the use of additional supplements like ginkgo and fish oil.
The user switched from finasteride to DIY dutasteride mesotherapy and topical minoxidil due to side effects. They report improved well-being and no hair loss worsening after stopping finasteride.
Finasteride may inhibit melanin production, affecting tanning and causing white hairs in the beard and eyebrows. The user considers switching to oral Dutasteride or topical treatments to address these issues.
GT20029 and PP405 are discussed as potential alternatives or complements to finasteride for hair loss treatment. GT20029 is entering phase 3 trials, while PP405 is seen as promising for regrowing hair and possibly eliminating the need for other treatments.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
The user is frustrated with Koshinemall's disorganized service and delayed shipping of KX-826. They are seeking feedback on whether others have received their KX-826 orders.
Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
The user successfully overcame finasteride side effects by lowering the dosage and adding zinc and vitamin B6 supplements. They also micro-dosed dutasteride and resumed weight lifting.